BTS Research’s, Sam Abunadi President & CEO, urges the FDA to require “Clinical Trials” for Cannabis dose determination as a scheduled substance with not yet classified strands

  • Post author:
  • Post category:News

With many cities and states now approving cannabis products, and without a doctor note, the American population at large is being invited to be a part of an uncontrolled drug…

Continue ReadingBTS Research’s, Sam Abunadi President & CEO, urges the FDA to require “Clinical Trials” for Cannabis dose determination as a scheduled substance with not yet classified strands